Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)
Authors:
- 1 March 1995
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 5 (2) , 134-142
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapyGynecologic Oncology, 1992
- Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of Ovarian cancerCancer, 1992
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: A preliminary reportGynecologic Oncology, 1990
- Total abdominal and pelvic radiotherapy in the management of early stage ovarian carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1988
- Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapyCancer, 1988
- Abdominopelvic radiotherapy in ovarian cancer. A 10-year experienceCancer, 1985
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinumCancer Chemotherapy and Pharmacology, 1983
- Reporting results of cancer treatmentCancer, 1981